Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Cyllene Therapeutics announced the appointment of Alyssa Levin to its Board of Directors as Audit Committee Chair, along with two key executive hires: Clara Cambon-Thiebaud as VP of Regulatory Affairs and Céline Breda as VP of Chemistry, Manufacturing and Controls. These appointments strengthen the company's leadership as it advances its lead candidate EG110A toward late-stage clinical development for neurogenic bladder-related incontinence.